bluebird bio Inc expected to post a loss of 64 cents a share - Earnings Preview

bluebird bio

03/05/2024 16:44

* bluebird bio Inc  BLUE.OQ   BLUE.O  is expected to show a
rise
in quarterly revenue when it reports  results on May 7
(estimated) for the period ending December 31 2023
    * The Somerville Massachusetts-based  company is expected to
report a 16,290.8% increase in revenue to $10.162 million from
$62 thousand a year ago, according to the mean estimate from 11
analysts, based on LSEG data. (Revenue is on total revenue
basis)
    * ​LSEG's mean analyst estimate for bluebird bio Inc is for
a loss
of 64 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 7
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for bluebird
bio Inc
is $4.00​, above​ its last closing price of $0.90. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.67       -0.67      -0.66     Beat    2.2
 Jun. 30 2023  -0.72       -0.72      -0.67     Beat    6.4
 Mar. 31 2023  -0.27       -0.37      0.21      Beat    156.8​
 Jan. 1 0001   -0.37       -0.44      -0.81     Missed  -85.8
 ​​Sep.        -1.12       -1.12      -0.94     Beat    15.8
 30 2022                                                
 Jan. 1 0001   -1.27       -1.24      -1.27     Missed  -2.7​
 Mar. 31 2022  -1.38       -1.39      -1.66     Missed  -19.2
 Jan. 1 0001   -1.85       -1.88      -2.14     Missed  -13.5
 This summary was machine generated May 3 at 15:44 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)